Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1990 Jul;66(777):502–525. doi: 10.1136/pgmj.66.777.502

Nephrology, dialysis and transplantation.

K Farrington 1, P Sweny 1
PMCID: PMC2429640  PMID: 2217007

Full text

PDF
502

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbott F., Jones S., Lockwood C. M., Rees A. J. Autoantibodies to glomerular antigens in patients with Wegener's granulomatosis. Nephrol Dial Transplant. 1989;4(1):1–8. [PubMed] [Google Scholar]
  2. Abrahams C., Lipson S., Ross L. Pathologic changes in the kidneys and other organs of dogs undergoing extracorporeal shock wave lithotripsy with a tubless lithotripter. J Urol. 1988 Aug;140(2):391–394. doi: 10.1016/s0022-5347(17)41642-9. [DOI] [PubMed] [Google Scholar]
  3. Akizawa T., Koshikawa S., Nakazawa R., Yoshida T., Kaneko M., Nitadori Y. Elimination of beta 2-microglobulin by a new polyacrylonitrile membrane dialyser: mechanism and physiokinetics. Nephrol Dial Transplant. 1989;4(5):356–365. doi: 10.1093/oxfordjournals.ndt.a091890. [DOI] [PubMed] [Google Scholar]
  4. Altmann P., Plowman D., Marsh F., Cunningham J. Aluminium chelation therapy in dialysis patients: evidence for inhibition of haemoglobin synthesis by low levels of aluminium. Lancet. 1988 May 7;1(8593):1012–1015. doi: 10.1016/s0140-6736(88)91840-5. [DOI] [PubMed] [Google Scholar]
  5. Anderson S., Meyer T. W., Rennke H. G., Brenner B. M. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985 Aug;76(2):612–619. doi: 10.1172/JCI112013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Anderson S., Meyer T. W., Rennke H. G., Brenner B. M. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985 Aug;76(2):612–619. doi: 10.1172/JCI112013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Anderson S., Rennke H. G., Brenner B. M. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986 Jun;77(6):1993–2000. doi: 10.1172/JCI112528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Assimos D. G., Boyce W. H., Furr E. G., Espeland M. A., Holmes R. P., Harrison L. H., Kroovand R. L., McCullough D. L. Selective elevation of urinary enzyme levels after extracorporeal shock wave lithotripsy. J Urol. 1989 Sep;142(3):687–690. doi: 10.1016/s0022-5347(17)38853-5. [DOI] [PubMed] [Google Scholar]
  9. Aster R. H. Plasma therapy for thrombotic thrombocytopenic purpura. Sometimes it works, but why? N Engl J Med. 1985 Apr 11;312(15):985–987. doi: 10.1056/NEJM198504113121510. [DOI] [PubMed] [Google Scholar]
  10. Atkinson D. E., Bourke E. Metabolic aspects of the regulation of systemic pH. Am J Physiol. 1987 Jun;252(6 Pt 2):F947–F956. doi: 10.1152/ajprenal.1987.252.6.F947. [DOI] [PubMed] [Google Scholar]
  11. Baba T., Murabayashi S., Takebe K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial. Diabetologia. 1989 Jan;32(1):40–44. doi: 10.1007/BF00265402. [DOI] [PubMed] [Google Scholar]
  12. Baker L. R., Abrams L., Roe C. J., Faugere M. C., Fanti P., Subayti Y., Malluche H. H. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int. 1989 Feb;35(2):661–669. doi: 10.1038/ki.1989.36. [DOI] [PubMed] [Google Scholar]
  13. Baldwin D. S., Neugarten J., Feiner H. D., Gluck M., Spinowitz B. The existence of a protracted course in crescentic glomerulonephritis. Kidney Int. 1987 Mar;31(3):790–794. doi: 10.1038/ki.1987.67. [DOI] [PubMed] [Google Scholar]
  14. Begun F. P., Lawson R. K., Kearns C. M., Tieu T. M. Electrohydraulic shock wave induced renal injury. J Urol. 1989 Jul;142(1):155–159. doi: 10.1016/s0022-5347(17)38702-5. [DOI] [PubMed] [Google Scholar]
  15. Bell G. M., Bernstein R. K., Laragh J. H., Atlas S. A., James G. D., Pecker M. S., Sealey J. E. Increased plasma atrial natriuretic factor and reduced plasma renin in patients with poorly controlled diabetes mellitus. Clin Sci (Lond) 1989 Aug;77(2):177–182. doi: 10.1042/cs0770177. [DOI] [PubMed] [Google Scholar]
  16. Bennett P. H. 'Microalbuminuria' and diabetes: a critique--assessment of urinary albumin excretion and its role in screening for diabetic nephropathy. Am J Kidney Dis. 1989 Jan;13(1):29–34. doi: 10.1016/s0272-6386(89)80111-8. [DOI] [PubMed] [Google Scholar]
  17. Bennett W. M., Walker R. G., Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial. Clin Nephrol. 1989 Mar;31(3):128–131. [PubMed] [Google Scholar]
  18. Bergström J., Alvestrand A., Bucht H., Gutierrez A. What is the role of controls in an outpatient department on progression of renal disease? Blood Purif. 1988;6(6):336–342. doi: 10.1159/000169562. [DOI] [PubMed] [Google Scholar]
  19. Bia M. J., Cooper K., Schnall S., Duffy T., Hendler E., Malluche H., Solomon L. Aluminum induced anemia: pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int. 1989 Nov;36(5):852–858. doi: 10.1038/ki.1989.271. [DOI] [PubMed] [Google Scholar]
  20. Blair H. C., Finch J. L., Avioli R., Crouch E. C., Slatopolsky E., Teitelbaum S. L. Micromolar aluminum levels reduce 3H-thymidine incorporation by cell line UMR 106-01. Kidney Int. 1989 May;35(5):1119–1125. doi: 10.1038/ki.1989.99. [DOI] [PubMed] [Google Scholar]
  21. Borke J. L., Minami J., Verma A. K., Penniston J. T., Kumar R. Co-localization of erythrocyte Ca++-Mg++ ATPase and vitamin D-dependent 28-kDa-calcium binding protein. Kidney Int. 1988 Aug;34(2):262–267. doi: 10.1038/ki.1988.174. [DOI] [PubMed] [Google Scholar]
  22. Bowsher W. G., Carter S., Philp T., Hudd C., Kellett M. J., Whitfield H. N., Wickham J. E. Clinical experience using the Wolf Piezolith device at 2 British stone centers. J Urol. 1989 Sep;142(3):679–682. doi: 10.1016/s0022-5347(17)38851-1. [DOI] [PubMed] [Google Scholar]
  23. Brezis M., Rosen S. N., Epstein F. H. The pathophysiological implications of medullary hypoxia. Am J Kidney Dis. 1989 Mar;13(3):253–258. doi: 10.1016/s0272-6386(89)80062-9. [DOI] [PubMed] [Google Scholar]
  24. Brown A. J., Dusso A., Lopez-Hilker S., Lewis-Finch J., Grooms P., Slatopolsky E. 1,25-(OH)2D receptors are decreased in parathyroid glands from chronically uremic dogs. Kidney Int. 1989 Jan;35(1):19–23. doi: 10.1038/ki.1989.3. [DOI] [PubMed] [Google Scholar]
  25. Buckalew V. M., Jr, Paschal-McCormick C. Natriuretic hormone: current status. Am J Nephrol. 1989;9(4):329–342. doi: 10.1159/000167989. [DOI] [PubMed] [Google Scholar]
  26. Buerkert J., Martin D., Trigg D., Simon E. Effect of reduced renal mass on ammonium handling and net acid formation by the superficial and juxtamedullary nephron of the rat. Evidence for impaired reentrapment rather than decreased production of ammonium in the acidosis of uremia. J Clin Invest. 1983 Jun;71(6):1661–1675. doi: 10.1172/JCI110921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Butkus D. E. Persistent high mortality in acute renal failure. Are we asking the right questions? Arch Intern Med. 1983 Feb;143(2):209–212. [PubMed] [Google Scholar]
  28. Bygren P., Cederholm B., Heinegård D., Wieslander J. Non-Goodpasture anti-GBM antibodies in patients with glomerulonephritis. Nephrol Dial Transplant. 1989;4(4):254–261. doi: 10.1093/oxfordjournals.ndt.a091868. [DOI] [PubMed] [Google Scholar]
  29. CRANE R. K. Hypothesis for mechanism of intestinal active transport of sugars. Fed Proc. 1962 Nov-Dec;21:891–895. [PubMed] [Google Scholar]
  30. Cameron J. S. Acute renal failure--the continuing challenge. Q J Med. 1986 Apr;59(228):337–343. [PubMed] [Google Scholar]
  31. Canavese C., Stratta P., Vercellone A. The case for oxygen free radicals in the pathogenesis of ischemic acute renal failure. Nephron. 1988;49(1):9–15. doi: 10.1159/000184978. [DOI] [PubMed] [Google Scholar]
  32. Carr S., Mbanya J. C., Thomas T., Keavey P., Taylor R., Alberti K. G., Wilkinson R. Increase in glomerular filtration rate in patients with insulin-dependent diabetes and elevated erythrocyte sodium-lithium countertransport. N Engl J Med. 1990 Feb 22;322(8):500–505. doi: 10.1056/NEJM199002223220803. [DOI] [PubMed] [Google Scholar]
  33. Chavers B. M., Bilous R. W., Ellis E. N., Steffes M. W., Mauer S. M. Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med. 1989 Apr 13;320(15):966–970. doi: 10.1056/NEJM198904133201503. [DOI] [PubMed] [Google Scholar]
  34. Chazan J. A., Blonsky S. L., Abuelo J. G., Pezzullo J. C. Increased body aluminum. An independent risk factor in patients undergoing long-term hemodialysis? Arch Intern Med. 1988 Aug;148(8):1817–1820. doi: 10.1001/archinte.148.8.1817. [DOI] [PubMed] [Google Scholar]
  35. Chugh K. S., Sakhuja V., Malhotra H. S., Pereira B. J. Changing trends in acute renal failure in third-world countries--Chandigarh study. Q J Med. 1989 Dec;73(272):1117–1123. [PubMed] [Google Scholar]
  36. Chung-Park M., Parveen T., Lam M. Acquired cystic disease of the kidneys and renal cell carcinoma in chronic renal insufficiency without dialysis treatment. Nephron. 1989;53(2):157–161. doi: 10.1159/000185730. [DOI] [PubMed] [Google Scholar]
  37. Counahan R., Winterborn M. H., White R. H., Heaton J. M., Meadow S. R., Bluett N. H., Swetschin H., Cameron J. S., Chantler C. Prognosis of Henoch-Schönlein nephritis in children. Br Med J. 1977 Jul 2;2(6078):11–14. doi: 10.1136/bmj.2.6078.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Couser W. G. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis. 1988 Jun;11(6):449–464. doi: 10.1016/s0272-6386(88)80079-9. [DOI] [PubMed] [Google Scholar]
  39. Couser W. G., Salant D. J. In situ immune complex formation and glomerular injury. Kidney Int. 1980 Jan;17(1):1–13. doi: 10.1038/ki.1980.1. [DOI] [PubMed] [Google Scholar]
  40. Cushner H. M., Copley J. B., Lindberg J. S., Foulks C. J. Calcium citrate, a nonaluminum-containing phosphate-binding agent for treatment of CRF. Kidney Int. 1988 Jan;33(1):95–99. doi: 10.1038/ki.1988.15. [DOI] [PubMed] [Google Scholar]
  41. Daly A. L., Velazquez L. A., Bradley S. F., Kauffman C. A. Mucormycosis: association with deferoxamine therapy. Am J Med. 1989 Oct;87(4):468–471. doi: 10.1016/s0002-9343(89)80836-8. [DOI] [PubMed] [Google Scholar]
  42. Damsgaard E. M., Frøland A., Jørgensen O. D., Mogensen C. E. Microalbuminuria as predictor of increased mortality in elderly people. BMJ. 1990 Feb 3;300(6720):297–300. doi: 10.1136/bmj.300.6720.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989 Apr;32(4):219–226. doi: 10.1007/BF00285287. [DOI] [PubMed] [Google Scholar]
  44. Delmez J. A., Tindira C., Grooms P., Dusso A., Windus D. W., Slatopolsky E. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest. 1989 Apr;83(4):1349–1355. doi: 10.1172/JCI114022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Delmez J., Weerts C., Lewis-Finch J., Windus D., Slatopolsky E. Accelerated removal of deferoxamine mesylate-chelated aluminum by charcoal hemoperfusion in hemodialysis patients. Am J Kidney Dis. 1989 Apr;13(4):308–311. doi: 10.1016/s0272-6386(89)80037-x. [DOI] [PubMed] [Google Scholar]
  46. Demontis R., Reissi D., Noel C., Boudailliez B., Westeel P. F., Leflon P., Brasseur J., Coevoet B., Fournier A. Indirect clinical evidence that 1 alpha OH vitamin D3 increases the intestinal absorption of aluminum. Clin Nephrol. 1989 Mar;31(3):123–127. [PubMed] [Google Scholar]
  47. Donadio J. V., Jr, Offord K. P. Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am J Kidney Dis. 1989 Dec;14(6):445–451. doi: 10.1016/s0272-6386(89)80143-x. [DOI] [PubMed] [Google Scholar]
  48. Druml W., Mitch W. E. Protein-restricted diets and progression of renal failure. Blood Purif. 1988;6(5):285–298. doi: 10.1159/000169556. [DOI] [PubMed] [Google Scholar]
  49. Drüeke T., Fauchet M., Fleury J., Lesourd P., Toure Y., Le Pailleur C., de Vernejoul P., Crosnier J. Effect of parathyroidectomy on left-ventricular function in haemodialysis patients. Lancet. 1980 Jan 19;1(8160):112–114. doi: 10.1016/s0140-6736(80)90602-9. [DOI] [PubMed] [Google Scholar]
  50. Dunnill M. S., Millard P. R., Oliver D. Acquired cystic disease of the kidneys: a hazard of long-term intermittent maintenance haemodialysis. J Clin Pathol. 1977 Sep;30(9):868–877. doi: 10.1136/jcp.30.9.868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Dusso A., Lopez-Hilker S., Lewis-Finch J., Grooms P., Brown A., Martin K., Slatopolsky E. Metabolic clearance rate and production rate of calcitriol in uremia. Kidney Int. 1989 Mar;35(3):860–864. doi: 10.1038/ki.1989.64. [DOI] [PubMed] [Google Scholar]
  52. Dusso A., Lopez-Hilker S., Rapp N., Slatopolsky E. Extra-renal production of calcitriol in chronic renal failure. Kidney Int. 1988 Sep;34(3):368–375. doi: 10.1038/ki.1988.190. [DOI] [PubMed] [Google Scholar]
  53. Eiser A. R., Slifkin R. F., Neff M. S. Intestinal mucormycosis in hemodialysis patients following deferoxamine. Am J Kidney Dis. 1987 Jul;10(1):71–73. doi: 10.1016/s0272-6386(87)80015-x. [DOI] [PubMed] [Google Scholar]
  54. Ellison D. H., Velázquez H., Wright F. S. Thiazide-sensitive sodium chloride cotransport in early distal tubule. Am J Physiol. 1987 Sep;253(3 Pt 2):F546–F554. doi: 10.1152/ajprenal.1987.253.3.F546. [DOI] [PubMed] [Google Scholar]
  55. Epstein M. Atrial natriuretic factor in patients with liver disease. Am J Nephrol. 1989;9(2):89–100. doi: 10.1159/000167944. [DOI] [PubMed] [Google Scholar]
  56. Eschbach J. W., Egrie J. C., Downing M. R., Browne J. K., Adamson J. W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987 Jan 8;316(2):73–78. doi: 10.1056/NEJM198701083160203. [DOI] [PubMed] [Google Scholar]
  57. Falk R. J., Jennette J. C. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988 Jun 23;318(25):1651–1657. doi: 10.1056/NEJM198806233182504. [DOI] [PubMed] [Google Scholar]
  58. Farrington K., Varghese Z., Chan M. K., Fernando O. N., Baillod R. A., Sweny P., Moorhead J. F. How complete is a total parathyroidectomy in uraemia? Br Med J (Clin Res Ed) 1987 Mar 21;294(6574):743–743. doi: 10.1136/bmj.294.6574.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Feinfeld D. A., Sherwood L. M. Parathyroid hormone and 1,25(OH)2D3 in chronic renal failure. Kidney Int. 1988 Jun;33(6):1049–1058. doi: 10.1038/ki.1988.110. [DOI] [PubMed] [Google Scholar]
  60. Felsenfeld A. J., Rodriguez M., Coleman M., Ross D., Llach F. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease. Kidney Int. 1989 Jun;35(6):1371–1378. doi: 10.1038/ki.1989.136. [DOI] [PubMed] [Google Scholar]
  61. Felson D. T., Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med. 1984 Dec 13;311(24):1528–1533. doi: 10.1056/NEJM198412133112402. [DOI] [PubMed] [Google Scholar]
  62. Ferrier C., Beretta-Piccoli C., Weidmann P., Gnädinger M. P., Shaw S., Suchecka-Rachon K., Saxenhofer H. Hypotension and renal impairment during infusion of atrial natriuretic factor in liver cirrhosis with ascites. Am J Nephrol. 1989;9(4):291–299. doi: 10.1159/000167983. [DOI] [PubMed] [Google Scholar]
  63. Floege J., Granolleras C., Deschodt G., Heck M., Baudin G., Branger B., Tournier O., Reinhard B., Eisenbach G. M., Smeby L. C. High-flux synthetic versus cellulosic membranes for beta 2-microglobulin removal during hemodialysis, hemodiafiltration and hemofiltration. Nephrol Dial Transplant. 1989;4(7):653–657. [PubMed] [Google Scholar]
  64. Fogazzi G. B., Pasquali S., Moriggi M., Casanova S., Damilano I., Mihatsch M. J., Zucchelli P., Ponticelli C. Long-term outcome of Schönlein-Henoch nephritis in the adult. Clin Nephrol. 1989 Feb;31(2):60–66. [PubMed] [Google Scholar]
  65. Froment D. P., Molitoris B. A., Buddington B., Miller N., Alfrey A. C. Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate. Kidney Int. 1989 Dec;36(6):978–984. doi: 10.1038/ki.1989.290. [DOI] [PubMed] [Google Scholar]
  66. Garel L., Filiatrault D., Robitaille P. Nephrocalcinosis in Bartter's syndrome. Pediatr Nephrol. 1988 Jul;2(3):315–317. doi: 10.1007/BF00858685. [DOI] [PubMed] [Google Scholar]
  67. Geck P., Heinz E. Secondary active transport: introductory remarks. Kidney Int. 1989 Sep;36(3):334–341. doi: 10.1038/ki.1989.201. [DOI] [PubMed] [Google Scholar]
  68. Georgaki-Angelaki H. N., Steed D. B., Chantler C., Haycock G. B. Renal function following acute renal failure in childhood: a long term follow-up study. Kidney Int. 1989 Jan;35(1):84–89. doi: 10.1038/ki.1989.11. [DOI] [PubMed] [Google Scholar]
  69. Gilbert B. R., Riehle R. A., Vaughan E. D., Jr Extracorporeal shock wave lithotripsy and its effect on renal function. J Urol. 1988 Mar;139(3):482–485. doi: 10.1016/s0022-5347(17)42498-0. [DOI] [PubMed] [Google Scholar]
  70. Gluck S. L. Cellular and molecular aspects of renal H+ transport. Hosp Pract (Off Ed) 1989 May 15;24(5):149-53, 157-60, 162-6. doi: 10.1080/21548331.1989.11703718. [DOI] [PubMed] [Google Scholar]
  71. Gotch F. A., Sargent J. A. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int. 1985 Sep;28(3):526–534. doi: 10.1038/ki.1985.160. [DOI] [PubMed] [Google Scholar]
  72. Gunasekaran S., Donovan J. M., Chvapil M., Drach G. W. Effects of extracorporeal shock wave lithotripsy on the structure and function of rabbit kidney. J Urol. 1989 May;141(5):1250–1254. doi: 10.1016/s0022-5347(17)41232-8. [DOI] [PubMed] [Google Scholar]
  73. Halperin M. L., Ethier J. H., Kamel K. S. Ammonium excretion in chronic metabolic acidosis: benefits and risks. Am J Kidney Dis. 1989 Oct;14(4):267–271. doi: 10.1016/s0272-6386(89)80200-8. [DOI] [PubMed] [Google Scholar]
  74. Halperin M. L. How much "new" bicarbonate is formed in the distal nephron in the process of net acid excretion? Kidney Int. 1989 Jun;35(6):1277–1281. doi: 10.1038/ki.1989.122. [DOI] [PubMed] [Google Scholar]
  75. Hansson S., Caugant D., Jodal U., Svanborg-Edén C. Untreated asymptomatic bacteriuria in girls: I--Stability of urinary isolates. BMJ. 1989 Apr 1;298(6677):853–855. doi: 10.1136/bmj.298.6677.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Hansson S., Jodal U., Lincoln K., Svanborg-Edén C. Untreated asymptomatic bacteriuria in girls: II--Effect of phenoxymethylpenicillin and erythromycin given for intercurrent infections. BMJ. 1989 Apr 1;298(6677):856–859. doi: 10.1136/bmj.298.6677.856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Hediger M. A., Coady M. J., Ikeda T. S., Wright E. M. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. 1987 Nov 26-Dec 2Nature. 330(6146):379–381. doi: 10.1038/330379a0. [DOI] [PubMed] [Google Scholar]
  78. Heidbreder E., Schafferhans K., Schramm D., Götz R., Heidland A. Toxic renal failure in the rat: beneficial effects of atrial natriuretic factor. Klin Wochenschr. 1986;64 (Suppl 6):78–82. [PubMed] [Google Scholar]
  79. Heidland A., Schaefer R. M., Heidbreder E., Hörl W. H. Catabolic factors in renal failure: therapeutic approaches. Nephrol Dial Transplant. 1988;3(1):8–16. [PubMed] [Google Scholar]
  80. Hirschberg R. R., Kopple J. D. Increase in renal plasma flow and glomerular filtration rate during growth hormone treatment may be mediated by insulin-like growth factor I. Am J Nephrol. 1988;8(3):249–254. doi: 10.1159/000167592. [DOI] [PubMed] [Google Scholar]
  81. Hopper A. H., Tindall H., Davies J. A. Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy. Nephrol Dial Transplant. 1989;4(2):140–143. [PubMed] [Google Scholar]
  82. Hostetter T. H., Olson J. L., Rennke H. G., Venkatachalam M. A., Brenner B. M. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol. 1981 Jul;241(1):F85–F93. doi: 10.1152/ajprenal.1981.241.1.F85. [DOI] [PubMed] [Google Scholar]
  83. Houghton D. C., English J., Bennett W. M. Chronic tubulointerstitial nephritis and renal insufficiency associated with long-term "subtherapeutic" gentamicin. J Lab Clin Med. 1988 Dec;112(6):694–703. [PubMed] [Google Scholar]
  84. Häberle D. A. Hemodynamic interactions between intrinsic blood flow control mechanisms in the rat kidney. Ren Physiol Biochem. 1988 Nov-Dec;11(6):289–315. [PubMed] [Google Scholar]
  85. Ihle B. U., Becker G. J., Whitworth J. A., Charlwood R. A., Kincaid-Smith P. S. The effect of protein restriction on the progression of renal insufficiency. N Engl J Med. 1989 Dec 28;321(26):1773–1777. doi: 10.1056/NEJM198912283212601. [DOI] [PubMed] [Google Scholar]
  86. Ittel T. H., Kluge R., Sieberth H. G. Enhanced gastrointestinal absorption of aluminium in uraemia: time course and effect of vitamin D. Nephrol Dial Transplant. 1988;3(5):617–623. doi: 10.1093/oxfordjournals.ndt.a091716. [DOI] [PubMed] [Google Scholar]
  87. Jensen T., Stender S., Goldstein K., Hølmer G., Deckert T. Partial normalization by dietary cod-liver oil of increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria. N Engl J Med. 1989 Dec 7;321(23):1572–1577. doi: 10.1056/NEJM198912073212304. [DOI] [PubMed] [Google Scholar]
  88. Johnson J. P., Moore J., Jr, Austin H. A., 3rd, Balow J. E., Antonovych T. T., Wilson C. B. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 1985 Jul;64(4):219–227. doi: 10.1097/00005792-198507000-00003. [DOI] [PubMed] [Google Scholar]
  89. Kahan B. D. Cyclosporine. N Engl J Med. 1989 Dec 21;321(25):1725–1738. doi: 10.1056/NEJM198912213212507. [DOI] [PubMed] [Google Scholar]
  90. Kainer G., Spence J. E., Chan J. C. X-linked hypophosphatemia: progress in characterization of genetic and metabolic defects. Nephron. 1989;51(4):449–453. doi: 10.1159/000185374. [DOI] [PubMed] [Google Scholar]
  91. Karmali M. A., Petric M., Lim C., Fleming P. C., Arbus G. S., Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985 May;151(5):775–782. doi: 10.1093/infdis/151.5.775. [DOI] [PubMed] [Google Scholar]
  92. Kasiske B. L., Velosa J. A., Halstenson C. E., La Belle P., Langendörfer A., Keane W. F. The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am J Kidney Dis. 1990 Jan;15(1):8–15. doi: 10.1016/s0272-6386(12)80586-5. [DOI] [PubMed] [Google Scholar]
  93. Kaye M., D'Amour P., Henderson J. Elective total parathyroidectomy without autotransplant in end-stage renal disease. Kidney Int. 1989 Jun;35(6):1390–1399. doi: 10.1038/ki.1989.138. [DOI] [PubMed] [Google Scholar]
  94. Kaysen G. A., Gambertoglio J., Jimenez I., Jones H., Hutchison F. N. Effect of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int. 1986 Feb;29(2):572–577. doi: 10.1038/ki.1986.36. [DOI] [PubMed] [Google Scholar]
  95. Keane W. F., Kasiske B. L., O'Donnell M. P. Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am J Nephrol. 1988;8(4):261–271. doi: 10.1159/000167599. [DOI] [PubMed] [Google Scholar]
  96. Kelepouris E. Renal handling of calcium. Am J Nephrol. 1988;8(3):226–234. doi: 10.1159/000167588. [DOI] [PubMed] [Google Scholar]
  97. Kincaid-Smith P., Fairley K. F., Kloss M. Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Q J Med. 1988 Oct;68(258):795–815. [PubMed] [Google Scholar]
  98. Kirschbaum B. B., Schoolwerth A. C. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci. 1989 Jan;297(1):9–11. doi: 10.1097/00000441-198901000-00003. [DOI] [PubMed] [Google Scholar]
  99. Kleinknecht D., Bobrie G., Meyer O., Noël L. H., Callard P., Ramdane M. Recurrent thrombosis and renal vascular disease in patients with a lupus anticoagulant. Nephrol Dial Transplant. 1989;4(10):854–858. doi: 10.1093/ndt/4.10.854. [DOI] [PubMed] [Google Scholar]
  100. Kleinman K. S., Coburn J. W. Amyloid syndromes associated with hemodialysis. Kidney Int. 1989 Feb;35(2):567–575. doi: 10.1038/ki.1989.25. [DOI] [PubMed] [Google Scholar]
  101. Kobayashi Y., Fujii K., Hiki Y., Tateno S. Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases. Q J Med. 1986 Oct;61(234):935–943. [PubMed] [Google Scholar]
  102. Krolewski A. S., Canessa M., Warram J. H., Laffel L. M., Christlieb A. R., Knowler W. C., Rand L. I. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med. 1988 Jan 21;318(3):140–145. doi: 10.1056/NEJM198801213180303. [DOI] [PubMed] [Google Scholar]
  103. Kurtz A., Schurek H. J., Jelkmann W., Muff R., Lipp H. P., Heckmann U., Eckardt K. U., Scholz H., Fischer J. A., Bauer C. Renal mesangium is a target for calcitonin gene-related peptide. Kidney Int. 1989 Aug;36(2):222–227. doi: 10.1038/ki.1989.183. [DOI] [PubMed] [Google Scholar]
  104. Lauer A., Saccaggi A., Ronco C., Belledonne M., Glabman S., Bosch J. P. Continuous arteriovenous hemofiltration in the critically ill patient. Clinical use and operational characteristics. Ann Intern Med. 1983 Oct;99(4):455–460. doi: 10.7326/0003-4819-99-4-455. [DOI] [PubMed] [Google Scholar]
  105. Leaker B., Cambridge G. Anti-neutrophil cytoplasmic antibodies and vasculitis. Postgrad Med J. 1990 Feb;66(772):77–79. doi: 10.1136/pgmj.66.772.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Lenz K., Hörtnagl H., Druml W., Grimm G., Laggner A., Schneeweisz B., Kleinberger G. Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis. Gut. 1989 Jan;30(1):90–96. doi: 10.1136/gut.30.1.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Levi M. Clinical disorders of renal tubular phosphate transport. Am J Med Sci. 1989 Sep;298(3):194–205. doi: 10.1097/00000441-198909000-00010. [DOI] [PubMed] [Google Scholar]
  108. Liaño F., García-Martín F., Gallego A., Orte L., Teruel J. L., Marcén R., Matesanz R., Ortuño J. Easy and early prognosis in acute tubular necrosis: a forward analysis of 228 cases. Nephron. 1989;51(3):307–313. doi: 10.1159/000185314. [DOI] [PubMed] [Google Scholar]
  109. Lin H. Y., Rocher L. L., McQuillan M. A., Schmaltz S., Palella T. D., Fox I. H. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989 Aug 3;321(5):287–292. doi: 10.1056/NEJM198908033210504. [DOI] [PubMed] [Google Scholar]
  110. Lin S. Y., Chaves C., Wiedemann E., Humphreys M. H. A gamma-melanocyte stimulating hormone-like peptide causes reflex natriuresis after acute unilateral nephrectomy. Hypertension. 1987 Dec;10(6):619–627. doi: 10.1161/01.hyp.10.6.619. [DOI] [PubMed] [Google Scholar]
  111. Lindqvist B., Wahlin A., Lundström B., Hofer P. A. Nonfamilial polycystic kidneys without enlargement. Nephron. 1985;39(2):134–140. doi: 10.1159/000183357. [DOI] [PubMed] [Google Scholar]
  112. Mabuchi H., Nakahashi H. A major endogenous ligand substance involved in renal failure. Nephron. 1988;49(4):277–280. doi: 10.1159/000185075. [DOI] [PubMed] [Google Scholar]
  113. Mactier R. A., Van Stone J., Cox A., Van Stone M., Twardowski Z. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol. 1987 Nov;28(5):222–226. [PubMed] [Google Scholar]
  114. Maher E. R., Robinson K. N., Scoble J. E., Farrimond J. G., Browne D. R., Sweny P., Moorhead J. F. Prognosis of critically-ill patients with acute renal failure: APACHE II score and other predictive factors. Q J Med. 1989 Sep;72(269):857–866. [PubMed] [Google Scholar]
  115. Malluche H. H., Faugere M. C. Aluminum-related bone disease. Blood Purif. 1988;6(1):1–15. doi: 10.1159/000169479. [DOI] [PubMed] [Google Scholar]
  116. Mangili R., Bending J. J., Scott G., Li L. K., Gupta A., Viberti G. Increased sodium-lithium countertransport activity in red cells of patients with insulin-dependent diabetes and nephropathy. N Engl J Med. 1988 Jan 21;318(3):146–150. doi: 10.1056/NEJM198801213180304. [DOI] [PubMed] [Google Scholar]
  117. Mann J., Ritz E. Preservation of kidney function by use of converting-enzyme inhibitors for control of hypertension. Lancet. 1987 Sep 12;2(8559):622–622. doi: 10.1016/s0140-6736(87)93006-6. [DOI] [PubMed] [Google Scholar]
  118. Marre M., Chatellier G., Leblanc H., Guyene T. T., Menard J., Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ. 1988 Oct 29;297(6656):1092–1095. doi: 10.1136/bmj.297.6656.1092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Massry S. G. Is parathyroid hormone a uremic toxin? Nephron. 1977;19(3):125–130. doi: 10.1159/000180876. [DOI] [PubMed] [Google Scholar]
  120. Mathiesen E. R., Borch-Johnsen K., Jensen D. V., Deckert T. Improved survival in patients with diabetic nephropathy. Diabetologia. 1989 Dec;32(12):884–886. doi: 10.1007/BF00297455. [DOI] [PubMed] [Google Scholar]
  121. McCord J. M. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985 Jan 17;312(3):159–163. doi: 10.1056/NEJM198501173120305. [DOI] [PubMed] [Google Scholar]
  122. Meyer R. A., Jr Humoral abnormalities in X-linked hypophosphatemic mice. Nephron. 1989;53(4):293–296. doi: 10.1159/000185770. [DOI] [PubMed] [Google Scholar]
  123. Meyrier A. Treatment of glomerular disease with cyclosporin A. Nephrol Dial Transplant. 1989;4(11):923–931. doi: 10.1093/ndt/4.11.923. [DOI] [PubMed] [Google Scholar]
  124. Miller L. R., Soffer O., Nassar V. H., Kutner M. H. Acquired renal cystic disease in end-stage renal disease: an autopsy study of 155 cases. Am J Nephrol. 1989;9(4):322–328. doi: 10.1159/000167988. [DOI] [PubMed] [Google Scholar]
  125. Minuth W. W., Steckelings U., Gross P. Complex physiological and biochemical action of aldosterone in toad urinary bladder and mammalian renal collecting duct cells. Ren Physiol. 1988;10(6):297–310. doi: 10.1159/000173139. [DOI] [PubMed] [Google Scholar]
  126. Mogensen C. E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed) 1982 Sep 11;285(6343):685–688. doi: 10.1136/bmj.285.6343.685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Mogensen C. E. Management of diabetic renal involvement and disease. Lancet. 1988 Apr 16;1(8590):867–870. doi: 10.1016/s0140-6736(88)91611-x. [DOI] [PubMed] [Google Scholar]
  128. Molitoris B. A., Froment D. H., Mackenzie T. A., Huffer W. H., Alfrey A. C. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int. 1989 Dec;36(6):949–953. doi: 10.1038/ki.1989.286. [DOI] [PubMed] [Google Scholar]
  129. Molitoris B. A., Froment D. H., Mackenzie T. A., Huffer W. H., Alfrey A. C. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int. 1989 Dec;36(6):949–953. doi: 10.1038/ki.1989.286. [DOI] [PubMed] [Google Scholar]
  130. Moorhead J. F., Chan M. K., El-Nahas M., Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982 Dec 11;2(8311):1309–1311. doi: 10.1016/s0140-6736(82)91513-6. [DOI] [PubMed] [Google Scholar]
  131. Morinière P., Cohen-Solal M., Belbrik S., Boudailliez B., Marie A., Westeel P. F., Renaud H., Fievet P., Lalau J. D., Sebert J. L. Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron. 1989;53(2):93–101. doi: 10.1159/000185718. [DOI] [PubMed] [Google Scholar]
  132. Nath K. A., Hostetter M. K., Hostetter T. H. Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest. 1985 Aug;76(2):667–675. doi: 10.1172/JCI112020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Nathan I., Hensel R., Dvilansky A., Shainkin-Kestenbaum R. Effect of uremic toxins--guanidino compounds and creatinine--on proliferation of HL60 and K562 cell lines. Nephron. 1989;52(3):251–252. doi: 10.1159/000185651. [DOI] [PubMed] [Google Scholar]
  134. Nicholls K. M., Fairley K. F., Dowling J. P., Kincaid-Smith P. The clinical course of mesangial IgA associated nephropathy in adults. Q J Med. 1984 Spring;53(210):227–250. [PubMed] [Google Scholar]
  135. Nordal K. P., Dahl E., Albrechtsen D., Halse J., Leivestad T., Tretli S., Flatmark A. Aluminium accumulation and immunosuppressive effect in recipients of kidney transplants. BMJ. 1988 Dec 17;297(6663):1581–1582. doi: 10.1136/bmj.297.6663.1581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. O'Donovan R., Baldwin D., Hammer M., Moniz C., Parsons V. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet. 1986 Apr 19;1(8486):880–882. doi: 10.1016/s0140-6736(86)90987-6. [DOI] [PubMed] [Google Scholar]
  137. Ofstad J., Iversen B. M. The interlobular artery: its possible role in preventing and mediating renal disorders. Nephrol Dial Transplant. 1988;3(2):123–129. [PubMed] [Google Scholar]
  138. Ono T., Iwamoto N., Kataoka H., Yamada S., Sakai Y., Kunitomo T. Clinical significance of a dialysis membrane that can remove beta 2-microglobulin (beta 2m). ASAIO Trans. 1988 Jul-Sep;34(3):342–345. [PubMed] [Google Scholar]
  139. Paganini E. P., Nakamoto S. Continuous slow ultrafiltration in oliguric acute renal failure. Trans Am Soc Artif Intern Organs. 1980;26:201–204. [PubMed] [Google Scholar]
  140. Paller M. S., Hedlund B. E. Role of iron in postischemic renal injury in the rat. Kidney Int. 1988 Oct;34(4):474–480. doi: 10.1038/ki.1988.205. [DOI] [PubMed] [Google Scholar]
  141. Paller M. S. Renal work, glutathione and susceptibility to free radical-mediated postischemic injury. Kidney Int. 1988 Apr;33(4):843–849. doi: 10.1038/ki.1988.75. [DOI] [PubMed] [Google Scholar]
  142. Parfrey P. S., Griffiths S. M., Barrett B. J., Paul M. D., Genge M., Withers J., Farid N., McManamon P. J. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med. 1989 Jan 19;320(3):143–149. doi: 10.1056/NEJM198901193200303. [DOI] [PubMed] [Google Scholar]
  143. Parving H. H., Andersen A. R., Smidt U. M., Svendsen P. A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983 May 28;1(8335):1175–1179. doi: 10.1016/s0140-6736(83)92462-5. [DOI] [PubMed] [Google Scholar]
  144. Parving H. H., Hommel E., Damkjaer Nielsen M., Giese J. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ. 1989 Aug 26;299(6698):533–536. doi: 10.1136/bmj.299.6698.533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Passlick J., Wilhelm M., Busch T., Grabensee B., Ohnesorge F. K. Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD. Clin Nephrol. 1989 Aug;32(2):96–100. [PubMed] [Google Scholar]
  146. Pedersen M. M., Mogensen C. E., Jørgensen F. S., Møller B., Lykke G., Pedersen O. Renal effects from limitation of high dietary protein in normoalbuminuric diabetic patients. Kidney Int Suppl. 1989 Nov;27:S115–S121. [PubMed] [Google Scholar]
  147. Peterson C., Madsen B., Perlman A., Chan A. Y., Myers B. D. Atrial natriuretic peptide and the renal response to hypervolemia in nephrotic humans. Kidney Int. 1988 Dec;34(6):825–831. doi: 10.1038/ki.1988.256. [DOI] [PubMed] [Google Scholar]
  148. Ponticelli C., Zucchelli P., Passerini P., Cagnoli L., Cesana B., Pozzi C., Pasquali S., Imbasciati E., Grassi C., Redaelli B. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1989 Jan 5;320(1):8–13. doi: 10.1056/NEJM198901053200102. [DOI] [PubMed] [Google Scholar]
  149. Portale A. A., Halloran B. P., Morris R. C., Jr Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest. 1989 May;83(5):1494–1499. doi: 10.1172/JCI114043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Potasman I., Better O. S. The role of secondary hyperparathyroidism in the anemia of chronic renal failure. Nephron. 1983;33(4):229–231. doi: 10.1159/000182958. [DOI] [PubMed] [Google Scholar]
  151. Pusey C. D., Lockwood C. M. Autoimmunity in rapidly progressive glomerulonephritis. Kidney Int. 1989 Apr;35(4):929–937. doi: 10.1038/ki.1989.77. [DOI] [PubMed] [Google Scholar]
  152. Rao T. K., Friedman E. A., Nicastri A. D. The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med. 1987 Apr 23;316(17):1062–1068. doi: 10.1056/NEJM198704233161705. [DOI] [PubMed] [Google Scholar]
  153. Rudin A. Bartter's syndrome. A review of 28 patients followed for 10 years. Acta Med Scand. 1988;224(2):165–171. [PubMed] [Google Scholar]
  154. Russell J., Lettieri D., Sherwood L. M. Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology. 1986 Dec;119(6):2864–2866. doi: 10.1210/endo-119-6-2864. [DOI] [PubMed] [Google Scholar]
  155. Savage C. O., Pusey C. D., Bowman C., Rees A. J., Lockwood C. M. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed) 1986 Feb 1;292(6516):301–304. doi: 10.1136/bmj.292.6516.301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  156. Savage C. O., Winearls C. G., Jones S., Marshall P. D., Lockwood C. M. Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet. 1987 Jun 20;1(8547):1389–1393. doi: 10.1016/s0140-6736(87)90591-5. [DOI] [PubMed] [Google Scholar]
  157. Sawyer N., Noonan K., Altmann P., Marsh F., Cunningham J. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients. Nephrol Dial Transplant. 1989;4(2):105–109. [PubMed] [Google Scholar]
  158. Schaefer K., Erley C. M., von Herrath D., Stein G. Calcium salts of ketoacids as a new treatment strategy for uremic hyperphosphatemia. Kidney Int Suppl. 1989 Nov;27:S136–S139. [PubMed] [Google Scholar]
  159. Schild L., Giebisch G., Karniski L. P., Aronson P. S. Effect of formate on volume reabsorption in the rabbit proximal tubule. J Clin Invest. 1987 Jan;79(1):32–38. doi: 10.1172/JCI112803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Schiller L. R., Santa Ana C. A., Sheikh M. S., Emmett M., Fordtran J. S. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med. 1989 Apr 27;320(17):1110–1113. doi: 10.1056/NEJM198904273201703. [DOI] [PubMed] [Google Scholar]
  161. Schneider H. W., Kulbe K. D., Weber H., Streicher E. In vitro and in vivo studies with a non-aluminum phosphate-binding compound. Kidney Int Suppl. 1986 Feb;18:S120–S123. [PubMed] [Google Scholar]
  162. Schneider H., Kulbe K. D., Weber H., Streicher E. High-effective aluminium free phosphate binder. In vitro and in vivo studies. Proc Eur Dial Transplant Assoc. 1983;20:725–730. [PubMed] [Google Scholar]
  163. Schreiber Z. A., Dave M. B. Acute renal failure in multiple myeloma after the ingestion of a contrast agent for cholecystography. Nephron. 1989;51(3):439–440. doi: 10.1159/000185348. [DOI] [PubMed] [Google Scholar]
  164. Schrier R. W., Arroyo V., Bernardi M., Epstein M., Henriksen J. H., Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988 Sep-Oct;8(5):1151–1157. doi: 10.1002/hep.1840080532. [DOI] [PubMed] [Google Scholar]
  165. Schrier R. W., Harris D. C., Chan L., Shapiro J. I., Caramelo C. Tubular hypermetabolism as a factor in the progression of chronic renal failure. Am J Kidney Dis. 1988 Sep;12(3):243–249. doi: 10.1016/s0272-6386(88)80130-6. [DOI] [PubMed] [Google Scholar]
  166. Schwab S. J., Hlatky M. A., Pieper K. S., Davidson C. J., Morris K. G., Skelton T. N., Bashore T. M. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med. 1989 Jan 19;320(3):149–153. doi: 10.1056/NEJM198901193200304. [DOI] [PubMed] [Google Scholar]
  167. Schwertschlag U. S., Dennis V. W., Tucker J. A., Camussi G. Nonimmunological alterations of glomerular filtration by s-PAF in the rat kidney. Kidney Int. 1988 Dec;34(6):779–785. doi: 10.1038/ki.1988.249. [DOI] [PubMed] [Google Scholar]
  168. Seaquist E. R., Goetz F. C., Rich S., Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989 May 4;320(18):1161–1165. doi: 10.1056/NEJM198905043201801. [DOI] [PubMed] [Google Scholar]
  169. Shapiro M. D., Nicholls K. M., Groves B. M., Kluge R., Chung H. M., Bichet D. G., Schrier R. W. Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients. Kidney Int. 1985 Aug;28(2):206–211. doi: 10.1038/ki.1985.142. [DOI] [PubMed] [Google Scholar]
  170. Shaw S. G., Weidmann P., Hodler J., Zimmermann A., Paternostro A. Atrial natriuretic peptide protects against acute ischemic renal failure in the rat. J Clin Invest. 1987 Nov;80(5):1232–1237. doi: 10.1172/JCI113197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  171. Sheikh M. S., Maguire J. A., Emmett M., Santa Ana C. A., Nicar M. J., Schiller L. R., Fordtran J. S. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest. 1989 Jan;83(1):66–73. doi: 10.1172/JCI113886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Sheinfeld J., Schaeffer A. J., Cordon-Cardo C., Rogatko A., Fair W. R. Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N Engl J Med. 1989 Mar 23;320(12):773–777. doi: 10.1056/NEJM198903233201205. [DOI] [PubMed] [Google Scholar]
  173. Sherrard D. J., Walker J. V., Boykin J. L. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. Am J Kidney Dis. 1988 Aug;12(2):126–130. doi: 10.1016/s0272-6386(88)80007-6. [DOI] [PubMed] [Google Scholar]
  174. Short C. D., Solomon L. R., Gokal R., Mallick N. P. Methylprednisolone in patients with membranous nephropathy and declining renal function. Q J Med. 1987 Nov;65(247):929–940. [PubMed] [Google Scholar]
  175. Silverman M. Molecular biology of the Na+-D-glucose cotransporter. Hosp Pract (Off Ed) 1989 Feb 15;24(2):180-4, 189-93, 197 passim. doi: 10.1080/21548331.1989.11703666. [DOI] [PubMed] [Google Scholar]
  176. Simpson H. K., Allison M. E., Telfer A. B. Improving the prognosis in acute renal and respiratory failure. Ren Fail. 1987;10(1):45–54. doi: 10.3109/08860228709047644. [DOI] [PubMed] [Google Scholar]
  177. Slatopolsky E., Weerts C., Lopez-Hilker S., Norwood K., Zink M., Windus D., Delmez J. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med. 1986 Jul 17;315(3):157–161. doi: 10.1056/NEJM198607173150304. [DOI] [PubMed] [Google Scholar]
  178. Slatopolsky E., Weerts C., Norwood K., Giles K., Fryer P., Finch J., Windus D., Delmez J. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int. 1989 Nov;36(5):897–903. doi: 10.1038/ki.1989.277. [DOI] [PubMed] [Google Scholar]
  179. Smithies M. N., Cameron J. S. Can we predict outcome in acute renal failure? Nephron. 1989;51(3):297–300. doi: 10.1159/000185312. [DOI] [PubMed] [Google Scholar]
  180. Soni A., Agarwal A., Chander P., Yoo J., Singal D., Salomon N., Robinson B., Treser G. Evidence for an HIV-related nephropathy: a clinico-pathological study. Clin Nephrol. 1989 Jan;31(1):12–17. [PubMed] [Google Scholar]
  181. Sprague S. M., Corwin H. L., Tanner C. M., Wilson R. S., Green B. J., Goetz C. G. Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients. Arch Intern Med. 1988 Oct;148(10):2169–2172. [PubMed] [Google Scholar]
  182. Stamm W. E., Hooton T. M., Johnson J. R., Johnson C., Stapleton A., Roberts P. L., Moseley S. L., Fihn S. D. Urinary tract infections: from pathogenesis to treatment. J Infect Dis. 1989 Mar;159(3):400–406. doi: 10.1093/infdis/159.3.400. [DOI] [PubMed] [Google Scholar]
  183. Starzl T. E., Todo S., Fung J., Demetris A. J., Venkataramman R., Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989 Oct 28;2(8670):1000–1004. doi: 10.1016/s0140-6736(89)91014-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  184. Stevens P. E., Riley B., Davies S. P., Gower P. E., Brown E. A., Kox W. Continuous arteriovenous haemodialysis in critically ill patients. Lancet. 1988 Jul 16;2(8603):150–152. doi: 10.1016/s0140-6736(88)90695-2. [DOI] [PubMed] [Google Scholar]
  185. Stone D. K., Xie X. S. Proton translocating ATPases: issues in structure and function. Kidney Int. 1988 Apr;33(4):767–774. doi: 10.1038/ki.1988.65. [DOI] [PubMed] [Google Scholar]
  186. Suki W. N. Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure. Arch Intern Med. 1989 Mar;149(3):669–673. [PubMed] [Google Scholar]
  187. Sundal E., Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant. 1989;4(11):979–987. doi: 10.1093/ndt/4.11.979. [DOI] [PubMed] [Google Scholar]
  188. Tam P. Y., Huraib S., Mahan B., LeBlanc D., Lunski C. A., Holtzer C., Doyle C. E., Vas S. I., Uldall P. R. Slow continuous hemodialysis for the management of complicated acute renal failure in an intensive care unit. Clin Nephrol. 1988 Aug;30(2):79–85. [PubMed] [Google Scholar]
  189. Teschner M., Heidland A. Hypercatabolism in acute renal failure--mechanisms and therapeutical approaches. Blood Purif. 1989;7(1):16–27. doi: 10.1159/000169569. [DOI] [PubMed] [Google Scholar]
  190. Turney J. H., Marshall D. H., Brownjohn A. M., Ellis C. M., Parsons F. M. The evolution of acute renal failure, 1956-1988. Q J Med. 1990 Jan;74(273):83–104. [PubMed] [Google Scholar]
  191. Waldo F. B., Alexander R., Wyatt R. J., Kohaut E. C. Alternate-day prednisone therapy in children with IgA-associated nephritis. Am J Kidney Dis. 1989 Jan;13(1):55–60. doi: 10.1016/s0272-6386(89)80117-9. [DOI] [PubMed] [Google Scholar]
  192. Walker J. D., Bending J. J., Dodds R. A., Mattock M. B., Murrells T. J., Keen H., Viberti G. C. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet. 1989 Dec 16;2(8677):1411–1415. doi: 10.1016/s0140-6736(89)92032-1. [DOI] [PubMed] [Google Scholar]
  193. Walser M., Drew H. H., LaFrance N. D. Creatinine measurements often yielded false estimates of progression in chronic renal failure. Kidney Int. 1988 Sep;34(3):412–418. doi: 10.1038/ki.1988.196. [DOI] [PubMed] [Google Scholar]
  194. Wehrmann M., Bohle A., Bogenschütz O., Eissele R., Freislederer A., Ohlschlegel C., Schumm G., Batz C., Gärtner H. V. Long-term prognosis of chronic idiopathic membranous glomerulonephritis. An analysis of 334 cases with particular regard to tubulo-interstitial changes. Clin Nephrol. 1989 Feb;31(2):67–76. [PubMed] [Google Scholar]
  195. Weiss L., Danielson B. G., Wikström B., Hedstrand U., Wahlberg J. Continuous arteriovenous hemofiltration in the treatment of 100 critically ill patients with acute renal failure: report on clinical outcome and nutritional aspects. Clin Nephrol. 1989 Apr;31(4):184–189. [PubMed] [Google Scholar]
  196. Williams P. S., Bone J. M. Immunosuppression can arrest progressive renal failure due to idiopathic membranous glomerulonephritis. Nephrol Dial Transplant. 1989;4(3):181–186. doi: 10.1093/oxfordjournals.ndt.a091853. [DOI] [PubMed] [Google Scholar]
  197. Windus D. W., Stokes T. J., Morgan J. R., Klahr S. The effects of atrial peptide in humans with chronic renal failure. Am J Kidney Dis. 1989 Jun;13(6):477–484. doi: 10.1016/s0272-6386(89)80005-8. [DOI] [PubMed] [Google Scholar]
  198. Winearls C. G., Oliver D. O., Pippard M. J., Reid C., Downing M. R., Cotes P. M. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986 Nov 22;2(8517):1175–1178. doi: 10.1016/s0140-6736(86)92192-6. [DOI] [PubMed] [Google Scholar]
  199. Woo K. T., Edmondson R. P., Yap H. K., Wu A. Y., Chiang G. S., Lee E. J., Pwee H. S., Lim C. H. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin Nephrol. 1987 Feb;27(2):56–64. [PubMed] [Google Scholar]
  200. Woolf A. S., Lyon T. L., Hoffbrand B. I., Cohen S. L., Moult P. J. Effects of physiological infusion of atrial natriuretic factor on healthy subjects and patients with the nephrotic syndrome. Nephron. 1989;52(3):244–250. doi: 10.1159/000185650. [DOI] [PubMed] [Google Scholar]
  201. Yanagisawa H., Wada O. Significant increase of IQ-type heterocyclic amines, dietary carcinogens in the plasma of patients with uremia just before induction of hemodialysis treatment. Nephron. 1989;52(1):6–10. doi: 10.1159/000185574. [DOI] [PubMed] [Google Scholar]
  202. Yokozawa T., Mo Z. L., Oura H. Comparison of toxic effects of methylguanidine, guanidinosuccinic acid and creatinine in rats with adenine-induced chronic renal failure. Nephron. 1989;51(3):388–392. doi: 10.1159/000185328. [DOI] [PubMed] [Google Scholar]
  203. Yoshida Y., Fogo A., Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int. 1989 Feb;35(2):654–660. doi: 10.1038/ki.1989.35. [DOI] [PubMed] [Google Scholar]
  204. Yudkin J. S., Forrest R. D., Jackson C. A. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet. 1988 Sep 3;2(8610):530–533. doi: 10.1016/s0140-6736(88)92657-8. [DOI] [PubMed] [Google Scholar]
  205. Zager R. A. A focus of tissue necrosis increases renal susceptibility to gentamicin administration. Kidney Int. 1988 Jan;33(1):84–90. doi: 10.1038/ki.1988.13. [DOI] [PubMed] [Google Scholar]
  206. Zager R. A., O'Quigley J., Zager B. K., Alpers C. E., Shulman H. M., Gamelin L. M., Stewart P., Thomas E. D. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis. 1989 Mar;13(3):210–216. doi: 10.1016/s0272-6386(89)80054-x. [DOI] [PubMed] [Google Scholar]
  207. Zucchelli P., Santoro A., Zucchelli A., Spongano M., Ferrari G. Long-term effects of parathyroidectomy on cardiac and autonomic nervous system functions in haemodialysis patients. Nephrol Dial Transplant. 1988;3(1):45–50. [PubMed] [Google Scholar]
  208. de la Serna F. J., Praga M., Gilsanz F., Rodicio J. L., Ruilope L. M., Alcazar J. M. Improvement in the erythropoiesis of chronic haemodialysis patients with desferrioxamine. Lancet. 1988 May 7;1(8593):1009–1011. doi: 10.1016/s0140-6736(88)91839-9. [DOI] [PubMed] [Google Scholar]
  209. el Nahas A. M., Coles G. A. Dietary treatment of chronic renal failure: ten unanswered questions. Lancet. 1986 Mar 15;1(8481):597–600. doi: 10.1016/s0140-6736(86)92819-9. [DOI] [PubMed] [Google Scholar]
  210. el Nahas A. M. Glomerulosclerosis: insights into pathogenesis and treatment. Nephrol Dial Transplant. 1989;4(10):843–853. doi: 10.1093/ndt/4.10.843. [DOI] [PubMed] [Google Scholar]
  211. van der Woude F. J., Rasmussen N., Lobatto S., Wiik A., Permin H., van Es L. A., van der Giessen M., van der Hem G. K., The T. H. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985 Feb 23;1(8426):425–429. doi: 10.1016/s0140-6736(85)91147-x. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES